Update on strategies to increase HDL quantity and function (Q37504704)

20 August 2017

1 reference

title

Update on strategies to increase HDL quantity and function (English)

1 reference

20 August 2017

Danielle Duffy

1

1 reference

PubMed ID

19488077

20 August 2017

Daniel J Rader

series ordinal

2

1 reference

PubMed ID

19488077

20 August 2017

language of work or name

English

0 references

publication date

2 June 2009

1 reference

Nature Reviews Cardiology

20 August 2017

1 reference

20 August 2017

6

1 reference

20 August 2017

7

1 reference

20 August 2017

455-463

1 reference

High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial

20 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

New insights into the regulation of HDL metabolism and reverse cholesterol transport

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Molecular regulation of HDL metabolism and function: implications for novel therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Multiple actions of high-density lipoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Apolipoprotein A-I(Milano): current perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effects of torcetrapib in patients at high risk for coronary events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Molecular identification of nicotinic acid receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Molecular identification of high and low affinity receptors for nicotinic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effect of torcetrapib on the progression of coronary atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Compromised LCAT function is associated with increased atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

A novel endothelial-derived lipase that modulates HDL metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Endothelial lipase is increased in vivo by inflammation in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

The macrophage foam cell as a target for therapeutic intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

ABC1: connecting yellow tonsils, neuropathy, and very low HDL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Synthetic LXR agonists increase LDL in CETP species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effects of intravenous infusion of lipid-free apo A-I in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

High-density lipoproteins as an emerging therapeutic target for atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.94

A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19488077

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clofibrate and niacin in coronary heart disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19488077

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19488077

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2009.94

1 reference

20 August 2017

1 reference

PubMed ID

19488077